IRMD Stock Overview
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
IRADIMED CORPORATION Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.70 |
| 52 Week High | US$51.04 |
| 52 Week Low | US$36.12 |
| Beta | 0.85 |
| 1 Month Change | 5.20% |
| 3 Month Change | -0.67% |
| 1 Year Change | -4.53% |
| 3 Year Change | 53.87% |
| 5 Year Change | 93.34% |
| Change since IPO | 351.52% |
Recent News & Updates
Recent updates
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
Feb 23
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
Feb 07Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
Nov 06Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Oct 13At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
Feb 05Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y
Oct 10IRadimed: Record Revenue Could Translate To Share Price Appreciation
Aug 23Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching
Aug 17iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M
Jul 29IRadimed: Reduce Equity Beta With Upside Capture
Jul 18IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively
Jul 13At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?
Feb 05Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital
Jan 12Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture
Jul 13iRadimed EPS beats by $0.04, beats on revenue
Apr 30iRadimed EPS misses by $0.02, beats on revenue
Feb 04Shareholder Returns
| IRMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.8% | 0.04% | 0.7% |
| 1Y | -4.5% | -0.9% | 23.9% |
Return vs Industry: IRMD underperformed the US Medical Equipment industry which returned -0.9% over the past year.
Return vs Market: IRMD underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| IRMD volatility | |
|---|---|
| IRMD Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IRMD has not had significant price volatility in the past 3 months.
Volatility Over Time: IRMD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 148 | Roger Susi | www.iradimed.com |
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.
IRADIMED CORPORATION Fundamentals Summary
| IRMD fundamental statistics | |
|---|---|
| Market cap | US$566.09m |
| Earnings (TTM) | US$17.92m |
| Revenue (TTM) | US$67.69m |
31.6x
P/E Ratio8.4x
P/S RatioIs IRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRMD income statement (TTM) | |
|---|---|
| Revenue | US$67.69m |
| Cost of Revenue | US$15.86m |
| Gross Profit | US$51.82m |
| Other Expenses | US$33.90m |
| Earnings | US$17.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.42 |
| Gross Margin | 76.57% |
| Net Profit Margin | 26.48% |
| Debt/Equity Ratio | 0% |
How did IRMD perform over the long term?
See historical performance and comparison